

# **ATTORNEY DOCKET NO.: 2003946-0058**



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Eisai Co., Ltd

Examiner:

Not Yet Assigned

Serial No.:

10/651,496

Art Unit:

1614

Filing Date:

August 29, 2003

Title:

Nitrogen-Containing Aromatic Derivatives

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## TRANSMITTAL LETTER

Enclosed are the following documents:

- 1. Form PTO-1449 (1 page);
- 2. Information Disclosure Statement (6 pages);
- 3. Transmittal Letter (1 page)
- 4. Cited Art (7); and
- 5. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,

Andrea L. C. Robidoux,

Reg. No. 47,902

Choate, Hall & Stewart Exchange Place 53 State Street Boston, MA 02109 (617) 248-5000 (617) 248-4000

Dated: 3774520

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Certificate of Mailing

Date

Signature

Sandra Saccocia

Typed or Printed Name of person signing certificate

ATTORNEY'S DOCKET NUMBER: 2003946-0058 HE UNITED STATES PATENT AND TRADEMARK OFFICE

Eisai Co., Ltd

Examiner: Not Yet Assigned Art Unit: 1614

Serial Number:

10/651,496

Filed:

August 29, 2003

Nitrogen-Containing Aromatic Derivatives Title:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## STATEMENT UNDER 37 C.F.R. §§ 1.56, 1.97, & 1.98

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

# Type of Statement

The present Information Disclosure Statement is:

- An original Information Disclosure Statement; or [X]
- A supplemental Information Disclosure Statement. []

	Certificate of Mailing
Service with sut	s correspondence is being deposited with the United States Postal fficient postage as Express Mail in an envelope addressed to for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
	Sandra Saccocia
,	Typed or Printed Name of person signing certificate

# Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

[X]	Pursuant to 37 CFR § 1.97(b); no fee or certification is required:					
	[]	Withi	n three months of the filing date of a national application other than			
		a cont	inued prosecution application under § 1.53(d);			
	[]	Within three months of the date of entry of the national stage as set forth				
		in <b>§ 1</b> .	491 in an international application;			
	[X]	Before	Before the mailing of a first Office action on the merits; or			
	[]	Before the mailing of a first Office action after the filing of a request for				
		contin	ued examination under § 1.114.			
[]	Pursu	Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing				
	date of any of a final action under § 1.113, a notice of allowance under § 1.311, or					
	an act	ion that	otherwise closes prosecution in the application; Applicant hereby			
either:						
	[ ] Certifies that either:					
		[]	each item of information contained in the information disclosure			
			statement was first cited in any communication from a foreign			
			patent office in a counterpart foreign application not more than			
			three months prior to the filing of the information disclosure			
			statement; or			
		[]	That no item of information contained in the information			
			disclosure statement was cited in a communication from a foreign			
			patent office in a counterpart foreign application, and, to the			

knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; or

			the information disclosure statement.; or	
	[]	Includ	les herewith the fee set forth in § 1.17(p).	
[ ] Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action			7 CFR § 1.97(d), after the mailing date of any final action under	
§ 1.113, a notice of allowance under § 1.311, or an action that otherwise of				
prosecution in the application; Applicant hereby both:				
	[ ] Certifies that either:			
		[]	each item of information contained in the information disclosure	
			statement was first cited in any communication from a foreign	
			patent office in a counterpart foreign application not more than	
			three months prior to the filing of the information disclosure	
			statement; or	
		[]	That no item of information contained in the information	
			disclosure statement was cited in a communication from a foreign	

disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; and

[ ] Includes herewith the fee set forth in § 1.17(p).

### Content of the Information Disclosure Statement

[X]

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

[ ]	Copies of references indicated with an asterisk on the attached form PTO-1449
	are not included pursuant to 37 CFR § 1.98(d) because they were previously
	provided to the United States Patent Office in an Information Disclosure

A copy of each cited reference not indicated with an asterisk is included;

Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier

effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status		

[ ] Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the aboveidentified application:

Applicant certifies that the Information Disclosure Statement either:

- [ ] Does not contain non-English language citations;
- [X] Does contain non-English language citations, for which an English language abstract is submitted.

- [ ] Does contain non-English language citations which were cited on an International Search Report (a copy of which is enclosed herewith).
- [ ] Includes one or more translations of a non-English citation.

#### Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b).

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
- 3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

Andrea L. C. Robidoux,

Reg. No. 47,902

CHOATE, HALL & STEWART Exchange Place 53 State Street Boston, Massachusetts 02109 (617) 248-5000 (617) 248-4000

Date:

3774512

Form PTO-1449 U.S. Department of Commerce				y. Docket:	In re Application No. 10/651,496		
(REV. 8-83)	DEC 0 6 2004 Detent and Trademork Office			2003946-0058 10/651,496 Applicant: Eisai Co., Ltd			
INFORMATION OF STATEMENT (Use several sheets if necessary)			Fili	ng Date: gust 29, 2003	Group:		
U.S. PATENT	DOCUMENTS		•			·	
Examiner's Initials	U.S. Patent No.	Applicant	Issu	e Date	Class	Subclass	
U.S. PATENT	APPLICATIONS		<u> </u>				
Examiner's Initials:	Serial Number:	Applicant:	Fili	ng Date:	Group:	Art Unit:	
FOREIGN PA	FOREIGN PATENT DOCUMENTS						
Examiner's Initials	Document No.	Country	Date	e	Translation Yes	on No	
	WO 02/32872	PCT	25 A	April 2002			
	WO 02/16348	PCT	+	February 2002			
OTHER DOC	UMENTS			and the state of t		<u> </u>	
Examiner's Initials							
	Folkman, J., "What is the Evidence That Tumors are Angiogenesis Dependent?", Journal of the National Cancer Institute, 82(1): 4-6, 1990.						
	Folkman, et al., "Clinical Applications of Research on Angiogenesis", <i>The New England Journal of Medicine</i> , <b>333</b> (26): 1757-1763, 1995.  Folkman, et al., "Angiogenesis", <i>The Journal of Biological Chemistry</i> , <b>267</b> (16): 10931-10934, 1992.  Hayek, et al., "An In Vivo Model for Study of the Angiogenic Effects of Basic Fibroblast Growth Factor", <i>Biochemical and Biophysical Research Communications</i> , <b>147</b> (2): 876-880, 1987.						
	Jakeman, et al., "Developmental Expression of Binding Sites and Messenger Ribonucleic Acid for Vascular Endothelial Growth Factor Suggests a Role for This Protein in Vasculogenesis and Angiogenesis", <i>Endocrinology</i> , <b>133</b> (2): 848-859, 1993.						
			· .				
EXAMINER				DATE CONSIDERED			
EVAMBLED		4	-4::	- :	al Maria	00. Duare lina	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.